14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
RNA vs GOCO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Avidity Biosciences, Inc. (RNA) is the stronger overall head-to-head candidate over GoHealth, Inc. (GOCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RNA carries a Unified Composite Score of 47.4/100 (HOLD) at $6.51 (N/M Forward P/E, -194.8% operating margin), whereas GOCO carries 42.9/100 (HOLD) at $0.30 (N/M Forward P/E, -292.0% operating margin).
Technical & Structure Timing Caution: RNA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.5); meanwhile GOCO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RNA vs GOCO. Trailing 12-month operating profitability (RNA -194.8% vs GOCO -292.0%) and valuation multiples (RNA N/M vs GOCO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Insurance Brokers value chain with $8.5M market capitalization and -292.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RNA vs GOCO Key Questions & Quantitative Answers
As of Nov 17, 2026, Avidity Biosciences, Inc. (RNA) is the stronger overall head-to-head candidate over GoHealth, Inc. (GOCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). RNA carries a Unified Composite Score of 47.4/100 (HOLD) at $6.51 (N/M Forward P/E, -194.8% operating margin), whereas GOCO carries 42.9/100 (HOLD) at $0.30 (N/M Forward P/E, -292.0% operating margin). Technical & Structure Timing Caution: RNA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.5); meanwhile GOCO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RNA leads the Growth & Scale pillar: RNA posts +24.2% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-14.0% gross margin, -194.8% operating margin), compared with GOCO at -94.6% YoY revenue growth and +424.1% YoY earnings growth on $153M TTM revenue (57.3% gross margin, -292.0% operating margin). On trailing 12-month operating scale, RNA generates $39M in USD-normalized revenue versus $153M for GOCO. In operating R&D and SG&A reinvestment, RNA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GOCO.
GOCO screens cheaper on headline valuation multiples. RNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas GOCO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-96.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RNA (-95.0% ROE) versus GOCO (-289.9% ROE) capital efficiency.
In options market volatility and institutional positioning, RNA carries 0.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 63% Vol realized risk). By comparison, GOCO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.15β · 201% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.